Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML

Reuters

Feb 11

<a href="https://laohu8.com/S/SNTI">Senti Biosciences</a> Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML

Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The company recently presented positive clinical data from this study at the American Society of Hematology $(ASH)$ Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652651-en) on February 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2610958992"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2610958992\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2610958992?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-11 21:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2610958992","market":"fut","top_or_hot":-1,"title":"Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SNTI\">Senti Biosciences</a> Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The company recently presented positive clinical data from this study at the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652651-en) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSenti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-11 21:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SNTI\">Senti Biosciences</a> Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The company recently presented positive clinical data from this study at the American Society of Hematology <a href=\"https://laohu8.com/S/ASH\">$(ASH)$</a> Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652651-en) on February 11, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nNDLbzllmp:1","article_id":"2610958992","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2610958992","pubTimestamp":1770816909,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia . The company recently presented positive clinical data from this study at the American Society of Hematology  Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy  designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4139":"生物科技","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","SNTI":"Senti Biosciences, Inc.","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4539":"次新股","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H"},"translate_title":"Senti Biosciences完成SENTI-202治疗复发性或难治性AML的1期招募","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":0.9,"NDAQ":0.9},"content_text":"Senti Biosciences Completes Phase 1 Enrollment for SENTI-202 in Relapsed or Refractory AML\n    \n\n        Senti Biosciences Inc. announced the completion of enrollment in its Phase 1 clinical trial of SENTI-202, a CD33/FLT3-targeting Logic Gated CAR NK cell therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML). The company recently presented positive clinical data from this study at the American Society of Hematology $(ASH)$ Annual Meeting, demonstrating deep, MRD-negative, durable complete remissions and a favorable safety profile in a heavily pretreated patient population. SENTI-202 has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may expedite its development and review process. Senti Biosciences plans to engage with the U.S. Food and Drug Administration in the first half of 2026 to discuss the potential pivotal registration program for SENTI-202 in R/R AML and possible expansion to newly diagnosed and pediatric AML indications.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9652651-en) on February 11, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}